ORIGINAL ARTICLE
CD99 correlates with low cyclin D1, high topoisomerase 2 status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma
Submission date: 2015-02-16
Final revision date: 2015-08-09
Acceptance date: 2015-08-10
Publication date: 2015-10-23
Pol J Pathol 2015;66(3):269-275
KEYWORDS
TOPICS
ABSTRACT
CD99 is a protein initially described in the Ewing sarcoma family of tumors, but growing evidence has shown its expression in other tumors of mesenchymal, hematopoietic and even epithelial origin. Some articles report CD99 in metaplastic carcinoma of the breast, a subtype of breast carcinoma (BC) with pronounced epithelial to mesenchymal (EMT) phenotype. Our aim was to analyse the potential relationship between CD99 and selected EMT (vimentin, E-cadherin, Twist) and proliferation markers (Ki-67, c-myc, cyclin D1, topoisomerase 2), molecular subtypes of BC, as well as overall survival (OS) and progression-free survival (PFS).
In a group of 122 cases CD99 membrane expression was seen in 14 (11.5%) cases: strong in 11 (9%) and moderate in 3 (2.5%). Expression of CD99 correlated with low cyclin D1 index, high level of topoisomerase 2 expression and lack of progesterone receptor (PR) but not with EMT characteristics. Additionally, strong expression of CD99 correlated with triple negative molecular BC phenotype. CD99 was prognostically irrelevant for OS and PFS.
CD99 correlates with selected proliferative markers and low ER/PR receptor status but not with patients’ outcome in BC. Further studies are required to explain precisely its role in molecular pathogenesis of BC.
In a group of 122 cases CD99 membrane expression was seen in 14 (11.5%) cases: strong in 11 (9%) and moderate in 3 (2.5%). Expression of CD99 correlated with low cyclin D1 index, high level of topoisomerase 2 expression and lack of progesterone receptor (PR) but not with EMT characteristics. Additionally, strong expression of CD99 correlated with triple negative molecular BC phenotype. CD99 was prognostically irrelevant for OS and PFS.
CD99 correlates with selected proliferative markers and low ER/PR receptor status but not with patients’ outcome in BC. Further studies are required to explain precisely its role in molecular pathogenesis of BC.
REFERENCES (21)
1.
Dworzak MN, Fritsch G, Buchinger P, et al. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood 1994; 83: 415-425.
2.
Milanezi F, Pereira EM, Ferreira FV, et al. CD99/MIC-2 surface protein expression in breast carcinomas. Histopathology 2001; 39: 578-583.
3.
Folpe AL, Goldblum JR, Rubin BP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol 2005; 29: 1025-1033.
4.
Hartel PH, Jackson J, Ducatman BS, et al. (2006). CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker. J Cutan Pathol 2006; 33 Suppl. 2: 24-28.
5.
Pelmus M, Guillou L, Hostein I, et al. Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases. Am J Surg Pathol 2002; 26: 1434-1440.
6.
Lucas DR, Bentley G, Dan ME, et al. Ewing sarcoma vs lymphoblastic lymphoma. A comparative immunohistochemical study. Am J Clin Pathol 2001; 115: 11-17.
7.
Sung CO, Ko YH, Park S, et al. Immunoreactivity of CD99 in non-Hodgkin’s lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma. J Korean Med Sci 2005; 20: 952-956.
8.
Jung KC, Park WS, Bae YM, et al. Immunoreactivity of CD99 in stomach cancer. J Korean Med Sci 2002; 17: 483-489.
9.
Yoo SH, Han J, Kim TJ, et al. Expression of CD99 in pleomorphic carcinomas of the lung. J Korean Med Sci 2005; 20: 50-55.
10.
Lee EJ, Lee HG, Park SH, et al. (2003). CD99 type II is a determining factor for the differentiation of primitive neuroectodermal cells. Exp Mol Med 2003; 35: 438-447.
11.
Jung KC, Kim NH, Park WS, et al. The CD99 signal enhances Fas-mediated apoptosis in the human leukemic cell line, Jurkat. FEBS Lett 2003; 554: 478-484.
12.
Walker JA, Carder PJ. Utility of immunohistochemistry for CD99 in the identification of matrix-producing carcinoma of the breast. Histopathology 2003; 42: 300-301.
13.
Foroni C, Broggini M, Generali D, et al. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev 2012; 38: 689-697.
14.
Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
15.
Yilmaz KB, Pak I, Irkkan C, et al. Metaplastic carcinoma of the breast: clinicopathological features and immunohistochemical analysis. J BUON 2011; 16: 652-656.
16.
Liu T, Zhang X, Shang M, et al. Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer. J Surg Oncol 2013; 107: 188-194.
17.
Fondrevelle ME, Kantelip B, Reiter RE. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol Oncol 2009; 27: 268-276.
18.
Olszewski W, Pieńkowski T, Olszewski W, et al. Topoisomerase 2 status in invasive breast carcinoma - comparison of its clinical value according to immunohistochemical and fluorescence in situ hybridization methods of evaluation. Pol J Pathol 2014; 65: 283-290.
19.
Romero A, Caldés T, Díaz-Rubio E, et al. Topoisomerase 2 alpha: a real predictor of anthracycline efficacy? Clin Transl Oncol 2012; 14: 163-168.
20.
van Nes JG, de Kruijf EM, Putter H, et al. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res Treat 2012; 133: 49-59.
21.
Byun HJ, Hong IK, Kim E, et al. A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. J Biol Chem 2006; 281: 34833-34847.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
